First Tracks Biotherapeutics 3Q 2026: Net loss $31.4M, EPS $(0.88) — 10-Q Summary
First Tracks Biotherapeutics reported a net loss of $31.4M for 3Q 2026, a 25.1% improvement from the prior-year quarter. Diluted loss per share narrowed to $0.88. The company reported progress in its ANB033 and rosnilimab programs, including positive Phase 1b data for ANB033 in celiac disease and Phase 2b results for rosnilimab in rheumatoid arthritis.
How this was made

The 30-second read
Why it matters
Positive trial readouts could improve valuation despite a modest loss; investors may watch upcoming Phase 2 studies for further catalysts.
Market read
New clinical data provide a fresh catalyst for TRAX, potentially prompting short‑term price appreciation.
What to watch
Upcoming Phase 2 trials and potential regulatory timelines could moderate short‑term price moves.
Background
The article summarizes First Tracks Biotherapeutics' Q3 2026 10‑Q filing, highlighting financials and early clinical data.
Ticker impact
First Tracks Biotherapeutics filed its 10‑Q reporting a narrowed Q3 net loss and disclosed positive Phase 1b data for ANB033 in celiac disease and Phase 2b data for rosnilimab in rheumatoid arthritis.
potential upside as investors price in the positive efficacy signals from ANB033 and rosnilimab.
First‑time disclosure of trial results for a micro‑cap biotech typically moves the stock, and the data are favorable with no serious adverse events.
Market effects
May boost the broader biotech sector as early‑stage celiac and autoimmune data gain attention.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The narrowed loss may be outweighed by cash burn concerns; investors could remain cautious.
Key entities
- companyFirst Tracks Biotherapeutics, Inc.
Biopharma developing ANB033 and rosnilimab.